Becton Dickinson and Co. (NYSE:BDX) hit a new 52-week high during trading on Monday . The company traded as high as $177.78 and last traded at $176.94, with a volume of 392,449 shares changing hands. The stock had previously closed at $176.00.

A number of brokerages have commented on BDX. Bank of America Corp. reissued a “buy” rating on shares of Becton Dickinson and in a research note on Tuesday, July 12th. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Jefferies Group raised their price objective on Becton Dickinson and from $190.00 to $192.00 and gave the company a “buy” rating in a research note on Thursday, July 28th. Argus reissued a “buy” rating on shares of Becton Dickinson and in a research note on Sunday, June 12th. Finally, Evercore ISI cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Wednesday, June 1st. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $169.50.

The stock’s 50 day moving average is $172.08 and its 200 day moving average is $158.82. The stock has a market cap of $37.44 billion and a PE ratio of 47.16.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 5th. The company reported $2.18 earnings per share for the quarter, topping the consensus estimate of $2.02 by $0.16. During the same quarter in the previous year, the company earned $1.61 EPS. The company earned $3.07 billion during the quarter, compared to analysts’ expectations of $3.07 billion. The business’s quarterly revenue was up 49.5% on a year-over-year basis. Equities research analysts predict that Becton Dickinson and Co. will post $8.56 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 9th will be paid a $0.66 dividend. The ex-dividend date is Wednesday, September 7th. This represents a $2.64 annualized dividend and a dividend yield of 1.50%.

In other Becton Dickinson and news, Director Rebecca W. Rimel sold 684 shares of the stock in a transaction on Friday, May 6th. The stock was sold at an average price of $163.69, for a total transaction of $111,963.96. Following the sale, the director now directly owns 6,835 shares in the company, valued at approximately $1,118,821.15. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 37,933 shares of the stock in a transaction on Friday, May 13th. The shares were sold at an average price of $166.17, for a total value of $6,303,326.61. Following the sale, the chief executive officer now owns 207,225 shares in the company, valued at $34,434,578.25. The disclosure for this sale can be found here.

A number of hedge funds have modified their holdings of BDX. Turner Investments L.P. acquired a new stake in shares of Becton Dickinson and during the fourth quarter valued at approximately $1,109,000. Victory Capital Management Inc. increased its stake in shares of Becton Dickinson and by 42.1% in the fourth quarter. Victory Capital Management Inc. now owns 10,162 shares of the company’s stock valued at $1,566,000 after buying an additional 3,009 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Becton Dickinson and during the fourth quarter valued at approximately $1,636,000. Stephens Inc. AR increased its stake in shares of Becton Dickinson and by 238.5% in the fourth quarter. Stephens Inc. AR now owns 12,362 shares of the company’s stock valued at $1,905,000 after buying an additional 8,710 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. acquired a new stake in shares of Becton Dickinson and during the fourth quarter valued at approximately $2,162,000.

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.